Loading...

COGT COGENT BIOSCIENCES INC Contract Awards 8-K Filing

CGNT

CGT

COGENT BIOSCIENCES INC

(COGT)

2024 8-K

Show Summary

Summary

Equity Offerings

Product Expansion

Debt-Equity Swaps

Financial Statements

Financial Results

Clinical Trial Update

Financial Results

Clinical Trial Updates

Financial Results Announcement

FDA Alignment Announcement

Annual Meeting and Amendmen...

Earnings Reports

Unregistered Sales of Equit...

Financial Results Announcement

Private Placement

Positive Clinical Trial Dat...

Earnings Reports

Earnings Reports

Underwriting Agreement

Annual Meeting Approval

Positive Phase 3 PEAK trial...

Earnings Reports

Earnings Reports

External Links:

Cogent Biosciences has completed enrollment for its Phase 3 PEAK clinical trial for gastrointestinal stromal tumors and expects its Phase 2 SUMMIT trial for systemic mastocytosis to finish enrollment three months earlier than planned, by Q1 2025.

AI Assistant

COGENT BIOSCIENCES INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.